rs8032978: Understanding Genetic Markers for Trastuzumab Response
The genetic variant rs8032978 is an intergenic single nucleotide polymorphism that has been investigated for its potential association with heart-related side effects in patients treated with the medication trastuzumab. Research suggests this variant may serve as a predictive marker for cardiotoxicity in specific East Asian cohorts.
What each genotype means
Potential cardiotoxicity risk marker
This genotype has been investigated in Japanese and Singaporean cohorts as a potential marker for trastuzumab-induced cardiotoxicity. Research suggests this variant may be associated with an increased risk of heart-related side effects during treatment, though these findings are primarily based on specific Asian populations and require further validation. Please discuss your treatment plan and any cardiac monitoring with your oncologist or pharmacist.
Frequency data for this specific genotype is variable and depends significantly on ancestral background.
Potential cardiotoxicity risk marker
This genotype has been investigated in Japanese and Singaporean cohorts as a potential marker for trastuzumab-induced cardiotoxicity. Research suggests this variant may be associated with an increased risk of heart-related side effects during treatment, though these findings are primarily based on specific Asian populations and require further validation. Please discuss your treatment plan and any cardiac monitoring with your oncologist or pharmacist.
Frequency data for this specific genotype is variable and depends significantly on ancestral background.
Potential cardiotoxicity risk marker
This genotype has been investigated in Japanese and Singaporean cohorts as a potential marker for trastuzumab-induced cardiotoxicity. Research suggests this variant may be associated with an increased risk of heart-related side effects during treatment, though these findings are primarily based on specific Asian populations and require further validation. Please discuss your treatment plan and any cardiac monitoring with your oncologist or pharmacist.
Frequency data for this specific genotype is variable and depends significantly on ancestral background.
What is rs8032978?
The identifier rs8032978 refers to a specific single nucleotide polymorphism (SNP) located in the human genome. In genetics, a SNP represents a variation at a single position in a DNA sequence among individuals. This particular variant is classified as intergenic, meaning it is located in the non-coding regions of the genome that lie between genes. Because it does not sit within a protein-coding gene, it does not directly alter the structure of a protein. Instead, researchers study such variants to determine if they influence how nearby genes are regulated or if they serve as markers that are inherited alongside other functional genetic changes. Understanding these non-coding variants is a major focus of modern genomics, as they often provide clues about the complex genetic architecture underlying individual differences in health and drug response.
Research and Clinical Associations
The primary interest in rs8032978 stems from its investigation in the field of pharmacogenomics, which studies how genes affect a person's response to drugs. Specifically, researchers have examined whether this variant is associated with trastuzumab-induced cardiotoxicity, a condition where the heart muscle is weakened during treatment with the breast cancer medication trastuzumab. Studies involving Japanese and Singaporean cohorts have explored this link. While initial genome-wide association studies (GWAS) identified potential signals, subsequent replication efforts have provided a more nuanced picture. When combining data from multiple studies, researchers observed a statistical association between this variant and heart-related side effects in these specific populations. It is important to note that this evidence is currently limited to these specific ancestral groups, and the clinical utility of this marker is still being evaluated by the scientific community.
Interpreting the Evidence
When evaluating genetic research, it is crucial to distinguish between a statistical association and a clinical diagnosis. The findings regarding rs8032978 indicate that individuals carrying certain alleles may show a different risk profile for cardiotoxicity when treated with trastuzumab, but this does not mean the variant is a definitive cause of heart issues. The evidence strength for this association is considered moderate, as it relies on specific cohort studies rather than universal clinical guidelines. Furthermore, genetic markers often interact with environmental factors, lifestyle, and other medications, making the prediction of drug response highly complex. Because this research is ongoing and population-specific, it is not currently used as a standard diagnostic tool in routine clinical practice. Any concerns regarding medication side effects or genetic risk should always be discussed directly with a qualified healthcare provider or pharmacist who can interpret these findings in the context of your overall health.
What You Can Do With This Information
If you have received information about your status for rs8032978, it is important to view it as a piece of scientific data rather than a medical instruction. You cannot use this information to self-diagnose or to make decisions about your cancer treatment. If you are currently prescribed trastuzumab or are considering it, the most important step is to have an open conversation with your oncologist or cardiologist. They are best equipped to assess your individual risk for cardiotoxicity by considering your medical history, heart function tests, and other clinical factors. Genetic information is only one part of a much larger clinical picture. Never stop or change your medication regimen based on genetic test results without consulting your medical team, as they are responsible for balancing the benefits and risks of your specific treatment plan.
How common is this variant?
The frequency of the rs8032978 variant is variable and differs significantly across global populations, with specific research focus on its prevalence in Japanese and Singaporean cohorts.
Frequently asked questions
Is rs8032978 a diagnostic test for heart disease?
No, rs8032978 is not a diagnostic test for heart disease. It is a genetic marker that has been studied for its potential association with drug-induced side effects in specific populations, and it does not provide a clinical diagnosis.
Should I change my medication if I have this variant?
You should never change your medication based on genetic test results without consulting your doctor. Only a healthcare professional can evaluate your specific medical needs and determine the safest treatment plan for you.
Why is this variant only studied in Asian populations?
Genetic studies often focus on specific populations to reduce genetic diversity that could mask potential associations. While this variant was studied in Japanese and Singaporean cohorts, further research is needed to see if these findings apply to other ancestral groups.
Where can I find more information about my genetic results?
You should discuss any genetic results with a genetic counselor or your primary healthcare provider. They can help you understand the limitations of the data and what it means for your personal health.
Sources & further reading
Educational information only, last refreshed 10/2/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs8032978?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants
This variant was identified in GWAS studies as a candidate for trastuzumab-induced cardiotoxicity risk.
This SNP is part of a set of variants studied for their potential role in trastuzumab-induced cardiotoxicity in Asian populations.
This variant is associated with G6PD deficiency, which can lead to hemolytic anemia upon exposure to certain medications or fava beans.
This variant is a well-established marker in the VKORC1 gene often used in studies regarding warfarin sensitivity and dosing.
This 'Duffy-null' variant is associated with benign ethnic neutropenia and an increased risk of clozapine-induced neutropenia, while providing protection against Plasmodium vivax malaria.
This variant influences the rate of caffeine metabolism and sensitivity to caffeine intake.